Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase 1, Randomized, Double-blinded, Multicenter Study to Evaluate the Reactogenicity, Safety, and Immunogenicity of an Intranasal Adenovirus Vector COVID-19 Vaccine (BBV154) in Healthy Volunteers

NCT04751682 is registered in ClinicalTrials.gov with Bharat Biotech International Limited as lead sponsor.

NCT NCT04751682
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT04751682 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase 1, Randomized, Double-blinded, Multicenter Study to Evaluate the Reactogenicity, Safety, and Immunogenicity of an Intranasal Adenovirus Vector COVID-19 Vaccine (BBV154) in Healthy Volunteers
Lead sponsor
Bharat Biotech International Limited
Phase
Phase 1
Overall status
Completed
Start date
March 1, 2021
Completion date
November 30, 2021
Enrollment
175 (actual)
Sites
4

Conditions

As the registry lists them; a condition with its own page is linked.

sars-cov infection